{"id":40552,"date":"2004-04-01T12:02:00","date_gmt":"2004-04-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/strontium-zur-therapie-der-osteoporose"},"modified":"2004-04-01T12:02:00","modified_gmt":"2004-04-01T10:02:00","slug":"strontium-zur-therapie-der-osteoporose","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/","title":{"rendered":"Strontium zur Therapie der Osteoporose?"},"content":{"rendered":"<p>Die medikament\u00f6se Behandlung der Osteoporose haben wir mehrfach besprochen (1, 2). Sie ist schwierig und wegen unterschiedlicher Empfehlungen von Fachgesellschaften und Interessengruppen schwer durchschaubar. Ein gro\u00dfes Problem ist, da\u00df bei Diagnosestellung der Knochenabbau h\u00e4ufig bereits so weit fortgeschritten ist, da\u00df die antiresorptiven Therapiestrategien, wie z.B. Bisphosphonate, (zu) sp\u00e4t kommen und klinisch nur begrenzt wirksam sind. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die medikament\u00f6se Behandlung der Osteoporose haben wir mehrfach besprochen (1, 2). Sie ist schwierig und wegen unterschiedlicher Empfehlungen von Fachgesellschaften und Interessengruppen schwer durchschaubar. Ein gro\u00dfes Problem ist, da\u00df bei Diagnosestellung der Knochenabbau h\u00e4ufig bereits so weit fortgeschritten ist, da\u00df die antiresorptiven Therapiestrategien, wie z.B. Bisphosphonate, (zu) sp\u00e4t kommen und klinisch nur begrenzt wirksam sind. [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[756,783],"class_list":["post-40552","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-osteoporose","tag-strontiumranelat"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Strontium zur Therapie der Osteoporose? - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Strontium zur Therapie der Osteoporose? - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Die medikament\u00f6se Behandlung der Osteoporose haben wir mehrfach besprochen (1, 2). Sie ist schwierig und wegen unterschiedlicher Empfehlungen von Fachgesellschaften und Interessengruppen schwer durchschaubar. Ein gro\u00dfes Problem ist, da\u00df bei Diagnosestellung der Knochenabbau h\u00e4ufig bereits so weit fortgeschritten ist, da\u00df die antiresorptiven Therapiestrategien, wie z.B. Bisphosphonate, (zu) sp\u00e4t kommen und klinisch nur begrenzt wirksam sind. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2004-04-01T10:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/04\/Abbildung-2004-30b-1.gif\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Strontium zur Therapie der Osteoporose?\",\"datePublished\":\"2004-04-01T10:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/\"},\"wordCount\":661,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/04\\\/Abbildung-2004-30b-1.gif\",\"keywords\":[\"Osteoporose\",\"Strontiumranelat\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/\",\"name\":\"Strontium zur Therapie der Osteoporose? - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/04\\\/Abbildung-2004-30b-1.gif\",\"datePublished\":\"2004-04-01T10:02:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/04\\\/Abbildung-2004-30b-1.gif\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/04\\\/Abbildung-2004-30b-1.gif\",\"width\":500,\"height\":234},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/strontium-zur-therapie-der-osteoporose\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Strontium zur Therapie der Osteoporose?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Strontium zur Therapie der Osteoporose? - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/","og_locale":"de_DE","og_type":"article","og_title":"Strontium zur Therapie der Osteoporose? - Der Arzneimittelbrief","og_description":"Die medikament\u00f6se Behandlung der Osteoporose haben wir mehrfach besprochen (1, 2). Sie ist schwierig und wegen unterschiedlicher Empfehlungen von Fachgesellschaften und Interessengruppen schwer durchschaubar. Ein gro\u00dfes Problem ist, da\u00df bei Diagnosestellung der Knochenabbau h\u00e4ufig bereits so weit fortgeschritten ist, da\u00df die antiresorptiven Therapiestrategien, wie z.B. Bisphosphonate, (zu) sp\u00e4t kommen und klinisch nur begrenzt wirksam sind. [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2004-04-01T10:02:00+00:00","og_image":[{"url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/04\/Abbildung-2004-30b-1.gif","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Strontium zur Therapie der Osteoporose?","datePublished":"2004-04-01T10:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/"},"wordCount":661,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/04\/Abbildung-2004-30b-1.gif","keywords":["Osteoporose","Strontiumranelat"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/","name":"Strontium zur Therapie der Osteoporose? - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/04\/Abbildung-2004-30b-1.gif","datePublished":"2004-04-01T10:02:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/04\/Abbildung-2004-30b-1.gif","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/04\/Abbildung-2004-30b-1.gif","width":500,"height":234},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/strontium-zur-therapie-der-osteoporose\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Strontium zur Therapie der Osteoporose?"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40552"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40552\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}